Novel macrocyclic heteroaryl derivatives acting as non-receptor tyrosine-protein kinase TYK2 and/or JAK1 and/or JAK2 inhibitors have been reported in a Hangzhou Highlightll Pharmaceutical Co. Ltd.
In the study, "Melatonin receptor 1A variants as genetic cause ... and mitogen-activated protein kinase pathways, which triggered osteoblast senescence and bone loss. The findings point to a ...
Aberrant activation of the Src family of tyrosine kinases has been implicated in ... of combination therapy with epidermal growth factor receptor inhibition and cytotoxic chemotherapy.